Muscle & Brawn 2.0 is live! New Tools, Voice Reader, Compound Index, Features and more on the way. Want to explore what’s new → Click Here
Independent & reader-supported — every article medically reviewed

Peptides / Incretin and metabolic peptides

194 In the index

Retatrutide RETA

An experimental injectable weight-loss drug from a major drug company, working on three different appetite-hormone pathways at once, in late-stage human trials. Trial data show the largest weight loss reported so far among this class of drugs, though it remains unapproved while trials continue.

Also known as LY3437943, triple agonist

Effects Lose fat
Routes Subcutaneous
Legal status Unapproved / investigational
WADA Not listed

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; trial doses being finalized
Reported range Phase III trials: up to 12 mg once weekly, titrated
Route Subcutaneous injection
Frequency Once weekly
Duration Trial durations of up to 1-2 years

A triple GIP/GLP-1/glucagon receptor agonist (Eli Lilly) in late-stage trials showing some of the largest weight-loss results reported for this drug class; not FDA-approved as of this writing, so any current supply is unregulated.

Where this comes from Published Phase III clinical trial data (Eli Lilly)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.